ArticlePharmacy (Basel, Switzerland)2022

Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies.

Francisco Ibarra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.